Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALX-0061 in Rheumatoid Arthritis
NCT01284569Phase 2Completed
- Sponsor
- Sanofi
- Start
- Mar 2011
- Primary completion
- Sep 2012
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of vobarilizumab in rheumatoid arthritis (RA), sponsored by Sanofi. Started Mar 2011; status: completed.
02
Drugs
vobarilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01284569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01284569.